Details for Patent: 8,999,638
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,999,638 protect, and when does it expire?
Patent 8,999,638 protects FANAPT and is included in one NDA.
This patent has sixteen patent family members in seven countries.
Summary for Patent: 8,999,638
Title: | Method of treatment based on polymorphisms of the KCNQ1 gene |
Abstract: | The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation. |
Inventor(s): | Wolfgang; Curt D. (Germantown, MD), Polymeropoulos; Mihael H. (Potomac, MD) |
Assignee: | Vanda Pharmaceuticals, Inc. (Washington, DC) |
Application Number: | 13/263,074 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,999,638 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,999,638
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-001 | May 6, 2009 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | See Plans and Pricing | ||||
Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-002 | May 6, 2009 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | See Plans and Pricing | ||||
Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-003 | May 6, 2009 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | See Plans and Pricing | ||||
Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-004 | May 6, 2009 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | See Plans and Pricing | ||||
Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-005 | May 6, 2009 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,999,638
PCT Information | |||
PCT Filed | April 05, 2010 | PCT Application Number: | PCT/US2010/029921 |
PCT Publication Date: | October 14, 2010 | PCT Publication Number: | WO2010/117931 |
International Family Members for US Patent 8,999,638
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Canada | 2757713 | See Plans and Pricing | |||
European Patent Office | 2417267 | See Plans and Pricing | |||
European Patent Office | 3023506 | See Plans and Pricing | |||
European Patent Office | 3354753 | See Plans and Pricing | |||
Spain | 2604102 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |